Daiichi Sankyo is a global pharmaceutical company based in Japan. It was established in 2005 through the merger of Sankyo and Daiichi Pharmaceutical and is listed on the Tokyo Stock Exchange.
Cocrystal Pharma advanced CDI-988 in a Phase 1b norovirus study and received FDA Fast Track designation. Nuvation Bio reported $18.5 million in IBTROZI net product revenues and presented updated TRUST trial data. Nautilus Biotechnology progressed its proteomics platform toward commercialization, maintaining a cash runway through 2027.
BostonGene won the "Overall AI-based Analytics Company of the Year" award in the 9th annual AI Breakthrough Awards. Its platform pairs AI with molecular profiling to support oncology drug development decisions.
BostonGene announced a strategic collaboration with Daiichi Sankyo to integrate AI-driven analytics into an ADC development program. The company also revealed six abstracts will be presented at the EHA 2026 Congress in Stockholm. The research showcases integrated multiomics and predictive modeling for blood cancer treatment optimization.
FDA approves AstraZeneca and Daiichi Sankyo's Datroway for first-line TNBC patients not eligible for PD-1/L1 inhibitors, based on Phase III TROPION-Breast02 data showing a 21% reduction in risk of death versus chemotherapy.
Artificial intelligence is being adopted across clinical development and could shorten drug development timelines by roughly 18 months while lowering R&D spending by about 5%. Data provenance and consent frameworks remain key issues as pharma companies expand AI use.
Daiichi Sankyo is collaborating with BostonGene to integrate AI-driven translational intelligence into an antibody drug conjugate development programme. The work is aimed at biomarker discovery, response prediction, patient selection and trial design across its cancer pipeline.
Over 20 pharmaceutical companies are developing therapies for HER2-positive gastric cancer, with multiple Phase III trials launched in March 2026 testing novel combination treatments for advanced disease.
The US FDA granted priority review and the European Medicines Agency validated applications for Enhertu as post-neoadjuvant treatment for HER2-positive early breast cancer, based on Phase III trial data showing 53% reduction in recurrence risk.
Merck is diversifying its oncology pipeline beyond Keytruda as the blockbuster approaches patent cliffs, focusing on immune modulating therapies, antibody-drug conjugates, and tumor intrinsic treatments through strategic acquisitions and partnerships.
JPMorgan downgraded Blue Jet Healthcare to Underweight with a ₹330 target price, citing weak contrast media execution, bempedoic acid competitive threats, and a thin late-stage pipeline with no launches expected for two years.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07776691 |
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07743164 |
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07739966 |
A Study of DS-3939a in Participants With Solid Tumors |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07720284 |
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC |
RECRUITING | PHASE3 |
| NCT07701941 |
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07683754 |
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd |
NOT_YET_RECRUITING | PHASE3 |
| NCT07681882 |
First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors |
RECRUITING | PHASE1 |
| NCT07630974 |
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01) |
RECRUITING | PHASE1/PHASE2 |
| NCT07535359 |
Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer |
AVAILABLE | |
| NCT07474649 |
A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events |
NOT_YET_RECRUITING | PHASE3 |
